The MUC4/MMP9/EGFR combined low expression significantly predicted better survival in glioma patients in comparison with the ‘double high’ group and the difference was again more significant than the previous analysis that combined MMP9 and MUC4 only (without EGFR) (p = 0.004, Log-rank). The gene discussed is EGFR; the disease is central nervous system cancer.